PMC8138324_01
Summary of laboratory findings and clinical course. (A) Hematoxylin and eosin staining (original magnification, x400) and immunohistochemical staining for CD138 (original magnification, x100), Lambda (original magnification, x100), and CD38 (original magnification, x100), BCL-2 (original magnification, x100) and PD-1 (original magnification, x100) of the biopsy of the right subpleural extraosseous soft mass. (B) The patient presented with fever with the highest temperature at 39 C 14 days post-CAR-T cells infusion, and her serum ferritin level gradually rose to reach a peak level. The trends of serum interleukin (IL)-6, IL-10, and interferon gamma (IFN-gamma) concentrations and the expansion trend of CAR-T cells are also shown during the course of CAR-T therapy. (C) Multiple abnormal masses in the right lung disappeared and could not be detected by CT scanning 1 month post-CAR-T cell therapy. (D) The trends of the serum IgA, IgG, and monoclonal protein concentrations (M spike) throughout the treatment.
fmed-08-649824-g0001.jpg
PMC8138324_01_fmed-08-649824-g0001.jpg
F1
The pathological diagnosis suggested an EMM infiltration, whose genotype was CD38+, CD138+, Kappa-, Lambda+, CD20-, CD3-, Syn-, CgA-, CK-pan-, BCL-2-, PD-1-, and Ki-67 (80%) (Figure 1A). Her serum ferritin level and serum interleukin (IL)-6, IL-10, and interferon gamma (IFN-gamma) concentrations also gradually rose to reach a peak level during CAR-T cell expansion to peak (Figure 1B). The trends of the size of the subpleural soft mass before and after CAR-T cell therapy detected by CT are shown in Figure 1C. The trends of the serum IgA, IgG, and monoclonal protein concentrations (M spike) throughout the treatment are shown in Figure 1D.